vs

Side-by-side financial comparison of FORRESTER RESEARCH, INC. (FORR) and MEDIFAST INC (MED). Click either name above to swap in a different company.

FORRESTER RESEARCH, INC. is the larger business by last-quarter revenue ($101.1M vs $75.1M, roughly 1.3× MEDIFAST INC). On growth, FORRESTER RESEARCH, INC. posted the faster year-over-year revenue change (-6.5% vs -36.9%). FORRESTER RESEARCH, INC. produced more free cash flow last quarter ($-4.3M vs $-6.6M). Over the past eight quarters, FORRESTER RESEARCH, INC.'s revenue compounded faster (0.5% CAGR vs -34.4%).

Forrester Research, Inc. is a research and advisory firm working in research, consulting and events. Forrester’s clients include large global business, technology and consumer enterprises. The firm is headquartered in Cambridge, MA.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

FORR vs MED — Head-to-Head

Bigger by revenue
FORR
FORR
1.3× larger
FORR
$101.1M
$75.1M
MED
Growing faster (revenue YoY)
FORR
FORR
+30.4% gap
FORR
-6.5%
-36.9%
MED
More free cash flow
FORR
FORR
$2.4M more FCF
FORR
$-4.3M
$-6.6M
MED
Faster 2-yr revenue CAGR
FORR
FORR
Annualised
FORR
0.5%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FORR
FORR
MED
MED
Revenue
$101.1M
$75.1M
Net Profit
$-33.9M
Gross Margin
56.7%
69.4%
Operating Margin
-36.6%
-10.4%
Net Margin
-33.5%
Revenue YoY
-6.5%
-36.9%
Net Profit YoY
-7941.4%
EPS (diluted)
$-1.75
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FORR
FORR
MED
MED
Q4 25
$101.1M
$75.1M
Q3 25
$94.3M
$89.4M
Q2 25
$111.7M
$105.6M
Q1 25
$89.9M
$115.7M
Q4 24
$108.0M
$119.0M
Q3 24
$102.5M
$140.2M
Q2 24
$121.8M
$168.6M
Q1 24
$100.1M
$174.7M
Net Profit
FORR
FORR
MED
MED
Q4 25
$-33.9M
Q3 25
$-2.1M
$-2.3M
Q2 25
$3.9M
$2.5M
Q1 25
$-87.3M
$-772.0K
Q4 24
$432.0K
Q3 24
$-5.8M
$1.1M
Q2 24
$6.3M
$-8.2M
Q1 24
$-6.7M
$8.3M
Gross Margin
FORR
FORR
MED
MED
Q4 25
56.7%
69.4%
Q3 25
60.0%
69.5%
Q2 25
55.5%
72.6%
Q1 25
55.9%
72.8%
Q4 24
58.8%
74.1%
Q3 24
60.5%
75.4%
Q2 24
57.3%
73.2%
Q1 24
54.9%
72.8%
Operating Margin
FORR
FORR
MED
MED
Q4 25
-36.6%
-10.4%
Q3 25
4.7%
-4.6%
Q2 25
6.2%
-1.0%
Q1 25
-97.5%
-1.1%
Q4 24
-0.5%
0.6%
Q3 24
-0.7%
1.5%
Q2 24
9.3%
-4.7%
Q1 24
-9.3%
4.5%
Net Margin
FORR
FORR
MED
MED
Q4 25
-33.5%
Q3 25
-2.3%
-2.5%
Q2 25
3.5%
2.3%
Q1 25
-97.1%
-0.7%
Q4 24
0.4%
Q3 24
-5.7%
0.8%
Q2 24
5.2%
-4.8%
Q1 24
-6.7%
4.8%
EPS (diluted)
FORR
FORR
MED
MED
Q4 25
$-1.75
$-1.64
Q3 25
$-0.11
$-0.21
Q2 25
$0.20
$0.22
Q1 25
$-4.62
$-0.07
Q4 24
$0.02
$0.08
Q3 24
$-0.30
$0.10
Q2 24
$0.33
$-0.75
Q1 24
$-0.35
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FORR
FORR
MED
MED
Cash + ST InvestmentsLiquidity on hand
$63.3M
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$126.5M
$198.9M
Total Assets
$404.0M
$248.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FORR
FORR
MED
MED
Q4 25
$63.3M
$167.3M
Q3 25
$65.1M
$173.5M
Q2 25
$67.8M
$162.7M
Q1 25
$75.6M
$164.6M
Q4 24
$56.1M
$162.3M
Q3 24
$62.8M
$170.0M
Q2 24
$58.9M
$163.5M
Q1 24
$61.4M
$156.4M
Stockholders' Equity
FORR
FORR
MED
MED
Q4 25
$126.5M
$198.9M
Q3 25
$157.7M
$214.7M
Q2 25
$159.5M
$216.0M
Q1 25
$147.4M
$211.0M
Q4 24
$229.5M
$210.1M
Q3 24
$234.3M
$207.3M
Q2 24
$237.1M
$205.3M
Q1 24
$230.9M
$211.0M
Total Assets
FORR
FORR
MED
MED
Q4 25
$404.0M
$248.0M
Q3 25
$414.2M
$268.2M
Q2 25
$436.0M
$269.3M
Q1 25
$439.8M
$280.0M
Q4 24
$503.9M
$284.2M
Q3 24
$505.3M
$291.2M
Q2 24
$524.2M
$293.5M
Q1 24
$555.7M
$302.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FORR
FORR
MED
MED
Operating Cash FlowLast quarter
$-3.2M
$-5.3M
Free Cash FlowOCF − Capex
$-4.3M
$-6.6M
FCF MarginFCF / Revenue
-4.2%
-8.8%
Capex IntensityCapex / Revenue
1.1%
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$18.1M
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FORR
FORR
MED
MED
Q4 25
$-3.2M
$-5.3M
Q3 25
$1.2M
$12.1M
Q2 25
$-3.6M
$-3.4M
Q1 25
$26.7M
$3.4M
Q4 24
$-1.8M
$-4.9M
Q3 24
$264.0K
$9.1M
Q2 24
$-2.9M
$13.1M
Q1 24
$611.0K
$7.3M
Free Cash Flow
FORR
FORR
MED
MED
Q4 25
$-4.3M
$-6.6M
Q3 25
$524.0K
$10.8M
Q2 25
$-4.2M
$-4.8M
Q1 25
$26.1M
$1.9M
Q4 24
$-2.5M
$-7.2M
Q3 24
$-223.0K
$7.7M
Q2 24
$-3.7M
$11.1M
Q1 24
$-815.0K
$5.4M
FCF Margin
FORR
FORR
MED
MED
Q4 25
-4.2%
-8.8%
Q3 25
0.6%
12.0%
Q2 25
-3.8%
-4.5%
Q1 25
29.0%
1.6%
Q4 24
-2.3%
-6.1%
Q3 24
-0.2%
5.5%
Q2 24
-3.1%
6.6%
Q1 24
-0.8%
3.1%
Capex Intensity
FORR
FORR
MED
MED
Q4 25
1.1%
1.8%
Q3 25
0.7%
1.5%
Q2 25
0.5%
1.3%
Q1 25
0.7%
1.3%
Q4 24
0.6%
1.9%
Q3 24
0.5%
1.0%
Q2 24
0.7%
1.1%
Q1 24
1.4%
1.1%
Cash Conversion
FORR
FORR
MED
MED
Q4 25
Q3 25
Q2 25
-0.93×
-1.36×
Q1 25
Q4 24
-4.24×
Q3 24
8.04×
Q2 24
-0.46×
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FORR
FORR

Research Segment$82.2M81%
Consulting Segment$16.2M16%
Billable Expenses$1.5M2%
Professional Services$1.4M1%

MED
MED

Segment breakdown not available.

Related Comparisons